newsroom.csl1d
Global Newsroom
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL ...
newsroom.csl1d
Global Newsroom
MELBOURNE – 24 October 2024 – Two scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are developing ...
newsroom.csl2d
Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships
Two scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are ...
newsroom.csl8d
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III ...
newsroom.csl10d
CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources
SUMMIT, N.J., September 18, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal ...
newsroom.csl25d
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and ...